A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS sciences.

NeuroSense CEO, Alon Ben-Noon announced he will be joining award winning Broadway, television and film Star Aaron Lazar on a special live webinar to discuss further details on NeuroSense’s Amyotrophic lateral sclerosis (ALS) therapy treatments.

Lazar, a grammy nominated, SAG Award winner is using his demanding stage presence and established platform to confront ALS. Lazar diagnosed with ALS in January 2022, after which he began to advocate ALS treatments through keynote speaking and his platform “The Impossible Dream” to reach audiences nationwide. Lazar mentioned shortly following his diagnoses that his goal was to increase awareness of the disease and empower others to expand their knowledge.

Lazar spoke on his diagnoses in 2024 saying, “The ALS diagnosis was a turning point for me. I made a decision that for whatever life I have left I am not going to live it afraid. Somehow in the darkness, I found courage. The two years since have been the most transformative of my life.” ²

All in for ALS

Ben-Noon, NeuroSense CEO will accompany Lazar to discuss a variety of topics, with a focus on PrimeC, NeuroSense’s promising therapy treatment for ALS, alongside other topics including pressing news topics, NeuroSense scientific developments, correct market options, and Canadian regulation milestones.

PrimeC is Lazar’s focus during the discussion, with him specifically mentioning his desire to get Ben-Noon to share the full story behind the therapy treatment. PrimeC, NeuroSense’s leading drug candidate, is an extended release orally administered formulation comprised of a fixed-dose combination of Ciprofloxacin, and Cellecoxib both of which are FDA approved.

The treatment is engineered to target multiple key targets of ALS that effect:

• Motor neuron
• Degeneration, inflammation
• Iron accumulation,
• Impaired ribonucleic acid

In May 2025, NeuroSense announced its partnership with a global contract development and manufacturing organization to continue production of PrimeC, as well as secure future commercial supply. This positions PrimeC to rapidly expand into the Canadian market, a topic Lazar is eager to touch on in the webinar.

Ben-Noon mentioned the impact of the partnership saying, "This manufacturing milestone represents a critical leap forward in our commercialization roadmap, with commercial-scale production validated and a 36-month room-temperature shelf life confirmed, PrimeC is now positioned to rapidly enter the Canadian market upon regulatory approval. This achievement, coupled with our patent protection through 2042, strengthens our ability to deliver PrimeC to ALS patients who urgently need new therapeutic options." ³

All you need to know

Currently the show is slated to have a focus on questions and topics that Lazar has for Ben-Noon, yet selected questions from the shows participants are welcomed and will be answered during the live webcast. This invites the audience to actively participate in the conversation and allows for the conversation to engage voices outside of the two renown speakers.

The event is scheduled for Monday, August 4,2025 at 2:00 Pm EST, and will be available for participants to tune in through Zoom, and anyone who is interested can register for the webinar online.

Sources

1. Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community NeuroSense July 22, 2025 https://www.prnewswire.com/news-releases/awardwinning-broadway-television--film-star-aaron-lazar-featuring-neurosense-ceo-alon-bennoon-in-a-special-live-podcast-on-als-science-primecs-commercialization-strategies-and-community-302510730.html
2. Aaron Lazar- a champion in the ALS community ALS Network December 30, 2024 https://alsnetwork.org/aaron-lazar-a-champion-in-the-als-community/
3. NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch NeuroSense May 7, 2025 https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-successful-completion-of-commercial-manufacturing-scale-up-for-primec-in-preparation-for-potential-canadian-market-launch-302448613.html